Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Brief Summary: This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors. After a pre-randomisation period during which positron emission tomography computed tomography (PET/CT) and MRI will be conducted, patients will be randomized to receive either RO4607381 600mg po daily, or placebo po daily. PET/CT and MRI scans will be taken at intervals during the study. The anticipated time on study treatment is 2 years, and the target sample size is 100 individuals.


Options:
A: Arm Label: Dalcetrapib (RO4607381); Type: EXPERIMENTAL; Interventions: Drug: Dalcetrapib (RO4607381) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dalcetrapib (RO4607381); Assigned to Arm(s): Dalcetrapib (RO4607381) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: Rivaroxaban 2.5mg + Aspirin 100mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban 5mg + Aspirin Placebo; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban Placebo + Aspirin 100mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: Rivaroxaban placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Aspirin placebo; Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole placebo; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A